Payment overview · 2025
General Payments
$395,916.96
541 reported records · 22 companies
Healthcare provider profile · identity verified
George Scott Drew, DO
Allopathic & Osteopathic Physicians|Dermatology · MARION, OH · NPI 1245298009
Verified facts
What the public records show
CMS Open Payments records show George Scott Drew, DO received $395,916.96 in general payments during 2025 across 541 reported records.
ABBVIE INC. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Adbry, Opzelura, Otezla, Rinvoq, Siliq, Skyrizi, Sotyktu, Tremfya, Zoryve.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SKYRIZI as an associated drug or biological on 322790 records involving 36751 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Skyrizi by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Otezla by this doctor in 2024.
Arcutis Biotherapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Zoryve as an associated drug or biological on 56906 records involving 10745 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Zoryve by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sotyktu as an associated drug or biological on 35607 records involving 9242 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Sotyktu by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OPZELURA as an associated drug or biological on 59568 records involving 12571 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Opzelura by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Tremfya by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 4976 records involving 2737 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Tremfya by this doctor in 2024.
Kowa Pharmaceuticals America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZORYVE as an associated drug or biological on 22731 records involving 10996 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Zoryve by this doctor in 2024.
LEO Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ADBRY as an associated drug or biological on 37730 records involving 9327 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Adbry by this doctor in 2024.
Ortho Dermatologics, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SILIQ as an associated drug or biological on 3812 records involving 2101 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Siliq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $66,362.41 | 16.8% | 85 | 2025 |
| Arcutis Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $41,372.08 | 10.4% | 41 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $36,312.78 | 9.2% | 38 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $33,840.62 | 8.6% | 54 | 2025 |
| Galderma Laboratories, L.P. | Unresolved — no canonical attribution shown | $28,486.69 | 7.2% | 37 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $27,850.02 | 7.0% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23,194.12 | 5.9% | 23 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $22,391.52 | 5.7% | 42 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $20,863.36 | 5.3% | 19 | 2025 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20,652.60 | 5.2% | 30 | 2025 |
| LEO Pharma Inc. | Unresolved — no canonical attribution shown | $15,366.22 | 3.9% | 34 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15,331.15 | 3.9% | 10 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $14,745.30 | 3.7% | 34 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14,345.83 | 3.6% | 11 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $12,443.20 | 3.1% | 24 | 2025 |
| Journey Medical Corporation | Unresolved — no canonical attribution shown | $1,625.00 | 0.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $301.85 | 0.1% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $179.19 | 0.1% | 14 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $133.17 | 0.0% | 1 | 2025 |
| Biofrontera Inc. | Unresolved — no canonical attribution shown | $91.97 | 0.0% | 3 | 2025 |
| Medimetriks Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.08 | 0.0% | 1 | 2025 |
| MAYNE PHARMA COMMERCIAL LLC | Unresolved — no canonical attribution shown | $11.80 | 0.0% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $260,834.42 | 67 |
| Consulting Fee | $71,979.00 | 26 |
| Travel and Lodging | $41,948.15 | 97 |
| Food and Beverage | $11,475.39 | 349 |
| Compensation for serving as faculty or as a speaker for a medical education program | $9,680.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Arcutis Biotherapeutics, Inc., Kowa Pharmaceuticals America, Inc. | $56,703.23 | 51 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $51,340.99 | 53 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $36,445.95 | 39 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $33,835.41 | 53 | 2025 |
Source payment records
|
|||||
| NEMLUVIO Normalized: nemluvio |
Drug | Galderma Laboratories, L.P. | $28,468.33 | 35 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $27,701.32 | 31 | 2025 |
Source payment records
|
|||||
| EBGLYSS Normalized: ebglyss |
Drug | Lilly USA, LLC | $22,198.65 | 22 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $21,641.52 | 41 | 2025 |
Source payment records
|
|||||
| SILIQ Normalized: siliq |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $20,652.60 | 30 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $15,048.42 | 34 | 2025 |
Source payment records
|
|||||
| SPEVIGO Normalized: spevigo |
Biological, Drug | Boehringer Ingelheim Pharmaceuticals, Inc., LEO Pharma Inc. | $14,374.04 | 12 | 2025 |
Source payment records
|
|||||
| ILUMYA Normalized: ilumya |
Biological | SUN PHARMACEUTICAL INDUSTRIES INC. | $14,222.39 | 25 | 2025 |
Source payment records
|
|||||
| Sotyktu Normalized: sotyktu |
Drug | E.R. Squibb & Sons, L.L.C. | $12,443.20 | 24 | 2025 |
Source payment records
|
|||||
| ADBRY Normalized: adbry |
Biological | LEO Pharma Inc. | $10,887.67 | 19 | 2025 |
Source payment records
|
|||||
| LIBTAYO Normalized: libtayo |
Biological | Regeneron Healthcare Solutions, Inc. | $7,833.21 | 4 | 2025 |
Source payment records
|
|||||
| ANZUPGO Normalized: anzupgo |
Drug | LEO Pharma Inc. | $4,450.34 | 14 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $258.37 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $179.19 | 14 | 2025 |
Source payment records
|
|||||
| Cabtreo Normalized: cabtreo |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $104.50 | 5 | 2025 |
Source payment records
|
|||||
| JUBLIA Normalized: jublia |
Drug | Ortho Dermatologics, a division of Bausch Health US, LLC | $104.50 | 5 | 2025 |
Source payment records
|
|||||
| Winlevi Normalized: winlevi |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $53.68 | 1 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $48.08 | 5 | 2025 |
Source payment records
|
|||||
| Leqselvi Normalized: leqselvi |
Biological | SUN PHARMACEUTICAL INDUSTRIES INC. | $45.72 | 3 | 2025 |
Source payment records
|
|||||
| AMELUZ Normalized: ameluz |
Drug | Biofrontera Inc. | $44.16 | 2 | 2025 |
Source payment records
|
|||||
| Neo-Synalar Normalized: neo synalar |
Drug | Medimetriks Pharmaceuticals, Inc. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ADBRY adbry |
2025 | Adbry | 2024 | 56 | exact normalized | Medicare Part D |
| OPZELURA opzelura |
2025 | Opzelura | 2024 | 122 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 108 | exact normalized | Medicare Part D |
| SILIQ siliq |
2025 | Siliq | 2024 | 66 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SKYRIZI skyrizi |
2025 | Skyrizi | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Sotyktu sotyktu |
2025 | Sotyktu | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZORYVE zoryve |
2025 | Zoryve | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
108 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SKYRIZI open payments reported associated product |
CMS Open Payments — General Payments 322790 supporting records · 36751 recipient NPIs · example record 1201352600 |
Skyrizi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Arcutis Biotherapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Zoryve open payments reported associated product |
CMS Open Payments — General Payments 56906 supporting records · 10745 recipient NPIs · example record 1252324094 |
Zoryve · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | Sotyktu open payments reported associated product |
CMS Open Payments — General Payments 35607 supporting records · 9242 recipient NPIs · example record 1184377867 |
Sotyktu · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | OPZELURA open payments reported associated product |
CMS Open Payments — General Payments 59568 supporting records · 12571 recipient NPIs · example record 1225959946 |
Opzelura · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 4976 supporting records · 2737 recipient NPIs · example record 1174147664 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Kowa Pharmaceuticals America, Inc. Exact reporting entity; no affiliate inference |
2025 | ZORYVE open payments reported associated product |
CMS Open Payments — General Payments 22731 supporting records · 10996 recipient NPIs · example record 1243071225 |
Zoryve · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| LEO Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | ADBRY open payments reported associated product |
CMS Open Payments — General Payments 37730 supporting records · 9327 recipient NPIs · example record 1251989155 |
Adbry · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Ortho Dermatologics, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | SILIQ open payments reported associated product |
CMS Open Payments — General Payments 3812 supporting records · 2101 recipient NPIs · example record 1220077864 |
Siliq · 2024 Exact normalized brand match · 1 Part D row |
66 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Dupixent Pen | Dupilumab | 501 | 64 |
| Ammonium Lactate | Ammonium Lactate | 388 | 209 |
| Ketoconazole | Ketoconazole | 225 | 105 |
| Minoxidil | Minoxidil | 200 | 36 |
| Doxycycline Hyclate | Doxycycline Hyclate | 127 | 53 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 126 | 75 |
| Opzelura | Ruxolitinib Phosphate | 122 | 23 |
| Doxepin Hcl | Doxepin Hcl | 117 | 31 |
| Rinvoq | Upadacitinib | 108 | 14 |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 91 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 85 | 46 |
| Metronidazole | Metronidazole | 85 | 42 |
| Imiquimod | Imiquimod | 71 | 56 |
| Taltz Autoinjector | Ixekizumab | 67 | suppressed |
| Siliq | Brodalumab | 66 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 62 | 54 |
| Spironolactone | Spironolactone | 59 | 15 |
| Humira(Cf) Pen | Adalimumab | 58 | suppressed |
| Adbry | Tralokinumab-Ldrm | 56 | 11 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 48 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 46 | suppressed |
| Zoryve | Roflumilast | 40 | 15 |
| Dupixent Syringe | Dupilumab | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Tremfya | Guselkumab | 37 | suppressed |
| Vtama | Tapinarof | 35 | suppressed |
| Gabapentin | Gabapentin | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 23 |
| Acyclovir | Acyclovir | 29 | 16 |
| Otezla | Apremilast | 28 | suppressed |
| Pentoxifylline | Pentoxifylline | 28 | suppressed |
| Skyrizi Pen | Risankizumab-Rzaa | 27 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 23 | suppressed |
| Sotyktu | Deucravacitinib | 23 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 22 | suppressed |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 22 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Rifampin | Rifampin | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Skyrizi | Risankizumab-Rzaa | 13 | suppressed |
| Cosentyx Unoready Pen | Secukinumab | 12 | suppressed |
| Dapsone | Dapsone | 11 | suppressed |
| Fluocinolone Acetonide | Fluocinolone/Shower Cap | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $395,916.96 · 541 records | ABBVIE INC. | ADBRY, AMELUZ, ANZUPGO, Bimzelx, COSENTYX, Cabtreo, DUPIXENT, EBGLYSS, ILUMYA, JUBLIA, LIBTAYO, Leqselvi, NEMLUVIO, Neo-Synalar, OPZELURA, OTEZLA, RINVOQ, SILIQ, SKYRIZI, SPEVIGO, Sotyktu, TALTZ, TREMFYA, Winlevi, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Adbry play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error